This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): FG-3019
Description: FG-3019 is a monoclonal antibody directed against connective tissue growth factor (CTGF). CTGF is a growth factor that regulates cell proliferation, migration, and adhesion. It acts to promote fibroblast proliferation and extracellular matrix formation, among other things, and its overproduction has been proposed to play a major role in fibrosis pathways, especially those that are TGF-beta-dependent.
Deal Structure: In July 1998, Medarex and FibroGen entered into an antibody development agreement for potential anti-fibrotic therapies. Medarex could receive research and development payments, license fees and milestone payments plus royalty payments on future product sales by FibroGen. The agreement calls for Medarex to use its HuMAb-Mouse technology to produce fully human antibodies against FibroGen's proprietary targets for exclusive use by FibroGen and its licensees. FibroGen's targets include connective tissue growth factor (CTGF) and its processed fragments, bone morphogenic protein 1 and tolloids, keyproteins implicated in fibrotic disease. Potential payments by Fibrogen to Medarex could total $30 million, plus royalties.
In July 2009, Bristol-Myers Squibb and Medarex announced that the companies signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16.00 per share in cash.
In September 2009, Bristol-Myers Squibb completed its...See full deal structure in Biomedtracker
Partners: Bristol-Myers Squibb Company
Additional information available to subscribers only: